ReviewDiscover oncology2026
Pivotal role of long non-coding RNA in the development of new therapeutic approaches for plural mesothelioma.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pleural mesothelioma is a rare aggressive tumor that affects the parietal layer of the pleura. It constitutes 90% of mesotheliomas. Usually, the diagnosis takes place 30 to 40 years after asbestos exposure. Thus, patients are diagnosed at a very late stage, leading to a poor prognosis, with a low median survival rate of approximately one year and a 5-year survival rate of only 5%. The available treatment usually consists of a multimodal approach, including chemotherapy (platinum-based drugs and antifolates), surgery, and radiotherapy. Yet, new therapeutic approaches are still needed to achieve higher survival rates. Long non-coding RNAs are transcripts of more than 200 nucleotides and have been proven to participate in various cellular processes and biological mechanisms. Upon dysregulation, many biological pathways can be affected, initiating cancers or even promoting their aggressiveness. These non-coding RNAs have been studied for their therapeutic potential in various cancers. The role of long non-coding RNAs in PM, whether in regulating pathogenicity or as potential therapeutic targets, requires further investigation. This review highlights the role of lncRNAs in PM pathogenesis and their potential as therapeutic targets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.